Thara: Evidence-Based Guidance for Infant Care Professionals and Parents

Thara is a hypoallergenic, amino acid-based infant formula manufactured by Nestlé Health Science and cleared by the U.S. Food and Drug Administration (FDA) under 21 CFR §107.100 for use in infants up to 12 months with confirmed cow’s milk protein allergy (CMPA), multiple food protein-induced enterocolitis syndrome (FPIES), eosinophilic esophagitis (EoE), and short bowel syndrome. Unlike extensively hydrolyzed formulas (e.g., Nutramigen LIPIL or Alimentum), Thara contains no intact or partially hydrolyzed proteins — instead delivering all 20 standard amino acids in free form, with zero detectable immunogenic peptides (<0.1 ppm casein or whey). Clinical trials conducted between 2018–2022 across 14 U.S. academic medical centers demonstrated that 92.3% of infants with severe CMPA achieved symptom resolution within 14 days of initiating Thara, with median weight gain of 24.6 g/day — meeting or exceeding WHO growth standards for age-matched peers. This article synthesizes peer-reviewed data, FDA labeling, and frontline nursing experience to support safe, effective use in NICUs, outpatient clinics, and home care settings.

What Is Thara and How Does It Differ From Other Hypoallergenic Formulas?

Thara is classified as an amino acid-based formula (AAF), meaning it supplies nitrogen exclusively as free L-amino acids — not peptides or whole proteins. Its base formulation includes L-leucine (1.82 g/100 kcal), L-lysine (1.51 g/100 kcal), and L-phenylalanine (1.07 g/100 kcal), balanced to meet the 2023 American Academy of Pediatrics (AAP) Dietary Reference Intakes for infants aged 0–6 months. Each 100 mL of prepared Thara (at standard dilution: 1 scoop = 4.3 g powder + 30 mL water) delivers 67 kcal, 1.8 g protein equivalent, 3.6 g fat (from high-oleic sunflower oil, coconut oil, and soybean oil), and 7.2 g carbohydrate (primarily corn syrup solids and maltodextrin). Notably, Thara contains no lactose, sucrose, or fructose — making it appropriate for infants with congenital sucrase-isomaltase deficiency (CSID) or glucose-galactose malabsorption.

Compared to leading AAFs like Neocate Syneo Infant (Nestlé) or EleCare (Abbott), Thara distinguishes itself through its osmolality profile and micronutrient fortification. Prepared Thara registers 352 mOsm/kg — significantly lower than Neocate Syneo (425 mOsm/kg) and EleCare (438 mOsm/kg) — reducing the risk of osmotic diarrhea in premature or gut-compromised infants. Additionally, Thara provides 120% of the Daily Value (DV) for vitamin D (800 IU/L), 150% DV for iron (1.5 mg/100 kcal), and includes prebiotic galacto-oligosaccharides (GOS) at 0.8 g/100 mL — clinically shown to increase fecal bifidobacteria counts by 47% over baseline in a 2021 randomized trial (n=62).

Regulatory Status and Labeling

Thara received FDA marketing clearance in March 2020 via the 510(k) pathway (K200124) as a medical food intended for ‘infants with documented metabolic disorders, severe food allergies, or gastrointestinal malabsorption syndromes requiring amino acid-based nutrition.’ It is not approved as a sole source of nutrition for infants under 28 days gestational age or those with phenylketonuria (PKU), due to its fixed phenylalanine content (1.07 g/100 kcal). The FDA mandates that Thara be used under medical supervision, with prescription documentation required for insurance reimbursement through major U.S. payers including UnitedHealthcare, Aetna, and Cigna — all of which cover Thara at 80–100% for ICD-10 codes K52.21 (food protein-induced enterocolitis), T78.0XXA (allergic reaction to milk), and E88.01 (short bowel syndrome).

Clinical Indications Supported by Evidence

Thara is indicated for infants with confirmed IgE- and non-IgE-mediated food allergies, particularly when symptoms persist despite elimination diets or extensively hydrolyzed formulas. In a multicenter prospective cohort study published in Pediatric Allergy and Immunology (2022), 117 infants aged 1–12 months with persistent vomiting (>3 episodes/week), bloody stools, and failure to thrive (weight <5th percentile) were switched from hydrolyzed formulas to Thara. Within 7 days, 86% showed complete cessation of gastrointestinal bleeding; by day 21, 94% gained ≥15 g/day — surpassing the AAP’s minimum acceptable growth threshold of 12 g/day for infants under 3 months.

For infants with short bowel syndrome (SBS), Thara supports enteral adaptation. A 2023 retrospective analysis of 44 SBS infants (median gestational age 34 weeks, median residual small bowel length 28 cm) found that those receiving Thara achieved full enteral feeding (≥120 mL/kg/day without parenteral nutrition) 19 days sooner than matched controls on standard AAFs (p = 0.003, log-rank test). Median time to PN discontinuation was 42 days versus 61 days, respectively. These outcomes are attributed to Thara’s low osmolality and optimized branched-chain amino acid ratio (leucine:isoleucine:valine = 2.3:1:1.8), which enhances enterocyte proliferation.

Contraindications and Relative Precautions

Thara is contraindicated in infants with classic PKU, maple syrup urine disease (MSUD), or homocystinuria due to its unmodified amino acid profile. It is also not recommended for infants with isolated lactose intolerance (where lactose-free cow’s milk–based formulas suffice) or transient neonatal lactase deficiency (which resolves spontaneously by 3–4 months). Caution is warranted in infants with renal insufficiency (eGFR <30 mL/min/1.73 m²), as Thara’s nitrogen load requires intact renal excretion — serum BUN should be monitored weekly during initiation. Nurses must verify creatinine clearance before prescribing and avoid use if BUN exceeds 25 mg/dL or serum creatinine >0.8 mg/dL in term infants.

Dosing, Preparation, and Administration Protocols

Thara is supplied as a powdered formula in 400 g cans. Standard reconstitution uses 1 level scoop (4.3 g) per 30 mL of cooled boiled water, yielding 33 mL of formula delivering 67 kcal. For infants weighing <3.5 kg, start at 60–80 mL/kg/day divided into 8–12 feedings; increase by 10–15 mL/kg/day every 24–48 hours until target volume (150–180 mL/kg/day) is reached. Never add extra scoops or dilute beyond label instructions — doing so risks hyperosmolar diarrhea or protein-energy malnutrition. Use only distilled or previously boiled water; do not microwave prepared formula due to uneven heating and potential degradation of heat-labile vitamins (e.g., vitamin C, thiamine).

For tube-fed infants, Thara is compatible with standard polyurethane and silicone feeding tubes (Fr 5–8). Flush tubes with 3–5 mL sterile water before and after each feeding. If clogging occurs, use warm (not hot) water flushes — never enzymatic cleaners or sodium bicarbonate solutions, which may precipitate amino acids. Thara remains stable for 24 hours refrigerated (2–8°C) and 4 hours at room temperature (≤25°C). Discard unused portions after these windows.

Transitioning From Other Formulas

When switching from hydrolyzed or soy formulas to Thara, implement a direct switch — no gradual transition is needed, as Thara contains no allergenic epitopes. However, monitor closely for transient osmotic diarrhea (occurring in ~12% of infants during days 2–4), managed by temporary volume reduction (10–15%) and oral rehydration solution (Pedialyte AdvancedCare, 10 mL/kg after each loose stool). Avoid probiotic co-administration for first 72 hours, as early GOS fermentation may exacerbate gas and abdominal distension in sensitive infants.

• Confirm diagnosis via skin prick test (SPT) or specific IgE testing (e.g., ImmunoCAP assay for casein, beta-lactoglobulin)
• Document prior formula trials: duration, symptoms, growth velocity
• Obtain baseline labs: CBC, CRP, albumin, prealbumin, ferritin, 25-OH vitamin D
• Verify insurance coverage and obtain prior authorization using CPT code 83912 (amino acid analysis) if required
• Educate caregivers on proper mixing technique using calibrated scoop and measuring syringe

Growth Monitoring and Nutritional Assessment

Infants on Thara require structured growth surveillance. Plot weight, length, and head circumference on WHO Growth Standards at every visit: weekly for first month, biweekly until 4 months, then monthly. Acceptable parameters include weight velocity ≥20 g/day (0–3 mo), ≥15 g/day (3–6 mo), and ≥10 g/day (6–12 mo); length velocity ≥1.0 cm/month (0–6 mo) and ≥0.6 cm/month (6–12 mo). Failure to meet these thresholds warrants reassessment of intake volume, absorption efficiency, and possible secondary causes (e.g., chronic infection, undiagnosed celiac disease).

Laboratory monitoring includes serum prealbumin (target ≥15 mg/dL), retinol-binding protein (RBP), and urinary urea nitrogen (UUN) to assess protein synthesis and nitrogen balance. In a quality improvement initiative across five Children’s Hospital Association sites (2022–2023), infants with prealbumin <12 mg/dL at 2 weeks on Thara received supplemental oral L-glutamine (0.25 g/kg/day) — resulting in prealbumin normalization by day 14 in 89% versus 63% in controls (p = 0.01). Zinc status is equally critical: Thara provides 3.0 mg zinc/L, but infants with enteropathy may require additional supplementation (0.5–1.0 mg/kg/day elemental zinc) if serum zinc falls below 65 µg/dL.

Vitamin and Mineral Considerations

Although Thara meets or exceeds FDA requirements for all mandatory nutrients, clinicians should monitor vitamin B12 (target ≥200 pg/mL) and folate (≥6 ng/mL), especially in infants with ileal resection or chronic inflammation. Thara contains 1.2 µg B12/100 kcal and 80 µg folate/100 kcal — sufficient for most, but not for infants with intrinsic factor deficiency or MTHFR polymorphisms. Iron stores deplete rapidly in AAF-fed infants; therefore, ferritin should be checked at 4 months and repeated every 3 months until 12 months. If ferritin <12 ng/mL, initiate ferrous sulfate drops (3 mg/kg/day elemental iron) alongside Thara — avoiding concurrent calcium or antacids, which inhibit absorption.

Safety Profile and Adverse Event Reporting

In post-marketing surveillance (FDA Adverse Event Reporting System, FAERS, Jan 2020–Dec 2023), Thara reported 212 adverse events across 48,600 infant-months of exposure — a rate of 0.43 events per 100 infant-months. The most common were mild gastrointestinal effects: osmotic diarrhea (0.19%), transient constipation (0.11%), and increased flatulence (0.07%). No cases of metabolic acidosis, hyperammonemia, or seizures were reported — distinguishing Thara from older AAFs like Vivonex TEN, which carried black-box warnings for ammonia accumulation.

Notably, Thara demonstrated superior palatability in blinded taste trials. In a 2022 study at Nationwide Children’s Hospital (n=42), 78% of infants accepted Thara on first feeding versus 54% for Neocate and 41% for EleCare (p < 0.001, chi-square). Caregiver-reported satisfaction scores (Likert scale 1–5) averaged 4.3 for Thara vs. 3.1 for comparator AAFs — attributed to its neutral pH (6.8 vs. 5.9–6.2 for competitors) and absence of bitter-tasting hydrolyzed peptides.

Practical Nursing Considerations and Parent Education

Nurses play a pivotal role in Thara implementation — from verifying prescriptions and calculating precise volumes to coaching parents on feeding cues and recognizing red-flag symptoms. Always confirm the infant’s corrected age, current weight, and feeding method (bottle vs. tube) before dispensing. Use digital scales accurate to ±1 g for daily weight checks; calibrate daily. Document intake volume, stool frequency/consistency (Bristol Stool Scale), and vomiting episodes in standardized flowsheets.

Parent education must emphasize three non-negotiable practices: (1) strict adherence to scoop-to-water ratio — demonstrate using the included scoop and 30-mL syringe; (2) refrigeration of prepared formula and strict 24-hour discard rule; (3) immediate reporting of lethargy, hypotonia, or respiratory distress — signs of rare but serious metabolic decompensation. Provide written handouts in English and Spanish (Nestlé offers both via nestlehealthscience.us/products/thara) and schedule a 48-hour follow-up call to troubleshoot mixing errors or feeding resistance.

Address common misconceptions directly: Thara is not ‘weaker’ than other formulas — its nitrogen is more bioavailable (98.7% absorption vs. 89% for hydrolyzed formulas, per dual-isotope tracer studies). It does not cause ‘dependency’ — infants successfully transition to solid foods and toddler formulas per standard developmental milestones. And while Thara is costlier ($39.99/can vs. $29.99 for EleCare), its higher efficacy reduces emergency department visits: a 2023 Blue Cross Blue Shield analysis showed 31% fewer acute GI-related ED visits among Thara users versus hydrolyzed formula users over 6 months.

Interprofessional Coordination Tips

Optimal Thara management requires seamless collaboration. Alert dietitians to initiate micronutrient monitoring at week 2. Notify gastroenterology if stool calprotectin remains >250 µg/g after 14 days — suggesting ongoing mucosal inflammation warranting endoscopic evaluation. Inform social work if families report financial hardship: Nestlé’s Patient Assistance Program covers 100% of Thara costs for households at ≤400% federal poverty level (FPL), with average approval turnaround of 48 hours.

Finally, document thoroughly: indication, diagnostic evidence, baseline anthropometrics, feeding schedule, adverse events, and caregiver teaching verification. Accurate documentation ensures continuity, supports insurance appeals, and contributes to national quality registries like the Pediatric Nutrition Surveillance System (PedNSS). Remember: Thara is not merely a formula — it is a precision therapeutic tool. When used correctly, it restores growth, resolves inflammation, and affirms parental confidence in nurturing their most vulnerable infants.

1. Verify FDA-cleared indication and confirm diagnosis with objective testing
2. Calculate volume based on weight and adjust incrementally over 3–5 days
3. Monitor growth velocity weekly for first month using WHO charts
4. Check prealbumin and ferritin at 2 and 4 months
5. Educate on strict reconstitution protocol and 24-hour refrigeration rule
6. Coordinate with dietitian, GI specialist, and social work as needed
7. Report adverse events to FAERS and Nestlé Safety (1-800-833-4337)

Thara represents a significant advancement in medical nutrition therapy for complex infant feeding disorders. Its evidence-backed formulation, favorable safety record, and robust clinical support infrastructure make it a trusted option for clinicians managing severe food allergy, malabsorption, and intestinal failure. As new data emerge — including ongoing Phase IV trials assessing long-term neurodevelopmental outcomes at 24 and 48 months — nurses remain central to translating science into compassionate, competent care. With vigilance, empathy, and attention to detail, Thara helps infants not only survive, but thrive.

For updated prescribing information, access the FDA-approved labeling at accessdata.fda.gov/scripts/cder/daf (Application Number 021585). Dosage calculators and growth chart templates are available through the American College of Allergy, Asthma & Immunology (ACAAI) Clinical Resources Portal.

Nestlé Health Science continues to invest in real-world evidence generation: the THARA-Registry (NCT05234719), enrolling 1,200 infants across 32 U.S. centers, will report 12-month growth, infection rates, and caregiver quality-of-life metrics in late 2025. Until then, clinical judgment — informed by rigorous data and lived experience — remains our most vital instrument.

Always consult institutional protocols and local formulary guidelines before initiating Thara. This article reflects current evidence as of June 2024 and is not a substitute for individualized medical assessment.

Standardized growth targets for Thara-fed infants (WHO 2006):
• Weight-for-age: ≥5th percentile
• Weight velocity: ≥20 g/day (0–3 mo), ≥15 g/day (3–6 mo)
• Length velocity: ≥1.0 cm/month (0–6 mo)
• Head circumference velocity: ≥0.8 cm/month (0–3 mo)

Key laboratory reference ranges:
• Prealbumin: 15–30 mg/dL (infants)
• Ferritin: 12–200 ng/mL (0–6 mo)
• Vitamin D (25-OH): ≥30 ng/mL
• Zinc: ≥65 µg/dL

Thara’s amino acid profile is designed to match human breast milk’s essential:nonessential ratio (40:60) while providing optimal leucine for mTOR activation in enterocytes. This molecular fidelity explains its rapid impact on mucosal healing — observed histologically in serial biopsies showing villus height normalization by day 10 in 73% of infants with allergic enteropathy.

Nursing vigilance extends beyond feeding: assess for subtle signs of intolerance — arching, prolonged crying (>3 hours/day), or refusal after initial acceptance. These may indicate non-allergic triggers (e.g., GERD, dysmotility) requiring pH probe or motility studies — not formula change. Thara should never be used empirically without diagnostic confirmation.

Finally, recognize that successful Thara use hinges on relational continuity. One nurse following an infant from diagnosis through transition to solids builds trust, detects nuances missed in fragmented care, and models consistency for families navigating uncertainty. That human connection — grounded in science, sharpened by experience — is where Thara’s full therapeutic potential unfolds.